GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

AXS-05 was well-tolerated and significantly delayed the time to agitation relapse compared with placebo in patients with ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this ...

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

Researchers have discovered a way to get anti-inflammatory medicine across the blood-brain barrier, opening the door to ...